The Quantellect read.As of Nov 19, 2026, 7 active firms cover Alto Neuroscience, Inc: 6 rate it Buy or better, 1 sit at Neutral, and 0 rate it Sell or worse, a buy consensus. Targets range widely, $26.00 to $60.00 (about 2.3x), a sign of real disagreement on valuation. The average target of $38.83 sits 50% above the current $25.91. The rating mix has stayed broadly stable, with Buy-side ratings easing from 7 to 6 over recent months. On the fundamentals, the Street sees revenue growth near 0% this year and 0% next, consensus EPS building from about $-0.75 next quarter toward $-2.96 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS7 active firms
Buy
Strong Buy00%
Buy686%
Neutral114%
Sell00%
Strong Sell00%
Based on 7 active firms as of Nov 19, 2026 (365-day activity window).
12-MONTH PRICE TARGET
$38.83
+49.9% upside
Average target across 6 active firms as of Nov 19, 2026 vs $25.91 current
Highest Target$60.00
Average Target$38.83
Lowest Target$26.00
Detailed analyst forecasts for ANRO
Showing 1–6 of 6 named analysts shown · 7 active firms in the rating projection
As of Nov 19, 2026, 6 of 7 active firms rate ANRO a Buy (1 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
ANRO EPS & revenue forecast
EPS · NEXT QUARTER
$-0.75
Range $-1.02 – $-0.59 · 4 analysts · -7% YoY
Next period, 4 analysts expect Alto Neuroscience, Inc. to earn $-0.75 a share (range $-1.02 – $-0.59), versus $-0.80 a year earlier. Full-year consensus is $-2.54, growing to $-2.96 the year after.
REVENUE · NEXT QUARTER
$0
Range $0 – $0 · 4 analysts · +0% YoY
Revenue is expected to reach $0 (range $0 – $0), +0.0% year-over-year. Full-year consensus is $0, rising to $0 next year.
Top analysts covering Alto Neuroscience, Inc.
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on ANRO.
#1
Laura Chico
Wedbush · Rank #55
Neutral
$26.00+0.3% to target
Overall win rate
46%
+ Follow
#2
Keay Nakae
Chardan Capital · Rank #130
Buy
$30.00+15.8% to target
Overall win rate
41%
+ Follow
#3
Patrick R. Trucchio
HC Wainwright & Co. · Rank #308
Buy
$60.00+131.6% to target
Overall win rate
36%
+ Follow
#4
TA
Tazeen Ahmad
B of A Securities · Rank #411
Buy
No targeton ANRO
Overall win rate
46%
+ Follow
#5
Thomas Shrader
BTIG · Rank #553
Buy
$37.00+42.8% to target
Overall win rate
32%
+ Follow
ANRO stock forecast FAQ
What is ANRO's average 12-month price target?+
The 6 active firms with a live target average $38.83 for Alto Neuroscience, Inc. over the next 12 months, ranging from a $60.00 high to a $26.00 low, as of Nov 19, 2026.
Is ANRO stock a Buy, Sell or Neutral right now?+
The current consensus is Buy. Of the 7 active firms as of Nov 19, 2026, 6 rate it Buy or Strong Buy, 1 rate it Neutral, and 0 rate it Sell or Strong Sell.
What are the highest and lowest price targets for ANRO?+
The Street-high target is $60.00 (HC Wainwright & Co.), and the Street-low is $26.00 (Wedbush). The average of all 6 active-firm targets is $38.83.
How many active Wall Street firms cover ANRO?+
7 active firms have a recognized rating on Alto Neuroscience, Inc. as of Nov 19, 2026, and 6 active firms carry a live 12-month price target.
Who is the most accurate analyst covering ANRO?+
Among analysts who currently cover ANRO, Laura Chico of Wedbush has the strongest overall Quantellect track record (Rank #55). Their current call is Neutral with a $26.00 target.
What is Alto Neuroscience, Inc.'s projected EPS for next quarter?+
The consensus estimate is $-0.75 per share (range $-1.02 – $-0.59) across 4 analysts. Full-year EPS is projected at $-2.54, rising to $-2.96 the following year.
How much revenue is Alto Neuroscience, Inc. expected to report next quarter?+
Consensus revenue is $0 (range $0 – $0). Full-year revenue is projected at $0, growing to $0 next year.
Have analysts been upgrading or downgrading ANRO lately?+
As of Nov 19, 2026, 6 of 7 active firms rate ANRO a Buy (1 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their ANRO calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.